Immunex Message Board - Msg: 13399692

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim McMannis who wrote (410)	4/11/2000 5:47:00 PM
From: LemurHouse	Read Replies (2) of 656

Label expansion for Enbrel -- as was recommended by the FDA panel today -- will triple the on-label market for Enbrel. Actual label expansion probably won't happen for a couple of more months, with earnings to follow after that. So, the upside for the stock price won't all happen immediately. But today's news is huge, and will keep this stock moving strongly through the rest of this year, IMO. There is also the indication for CHF which could be a factor later in the year. Next year, we'll be looking for Nuvance results. If Nuvance results continue to be positive and if the drug makes it to market -- which looks probable at this point -- then this stock will experience an explosive move even bigger than the one caused by Enbrel. JMO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next